COA/ICORS2019: No effect on fracture healing, improved ROM with ketotifen fumarate for reducing PTJC
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
CONFERENCE ACE REPORTS
This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.
Synopsis
91 patients with elbow fractures included in the PERK clinical trial study were included in this sub-group analysis comparing fracture healing, functional outcomes and adverse events between oral ketotifen fumarate treatment and placebo. Follow up was performed at 12 and 52 weeks. Results revealed no significant differences between the ketotifen fumarate and placebo groups in fracture healing, inc...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.